Gonzalo Spera

Translational Research in Oncology — France

Medicine · Health Sciences

8h-index528citations64works0.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(29), Advanced Breast Cancer Therapies(20), Breast Cancer Treatment Studies(16), Cancer Treatment and Pharmacology(10), Monoclonal and Polyclonal Antibodies Research(6)

Publications64 total

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
ESMO Open·2025· 9 citedOpen Access
1074P Claudin- 6 (CLDN6) is a therapeutic target in ovarian cancer (OC): Emerging results from the CATALINA 1 (CAT1) study
Annals of Oncology·2025
LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes
Annals of Oncology·2025· 3 citedOpen Access
293MO TACTIVE-N: Phase 2 study of neoadjuvant vepdegestrant, a PROteolysis TArgeting chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer (BC)
Annals of Oncology·2025
369P Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in estrogen receptor-positive early breast cancer patients. A pooled analysis from GEICAM and TRIO trials
Annals of Oncology·2025
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials
The Oncologist·2025Open Access
Abstract P3-11-10: Benefit/risk relationship of TCH versus AC-TH in BCIRG 006: analysis using generalized pairwise comparisons
Clinical Cancer Research·2025
2909 "ESCAPE from the Control ROOM": A Pilot Study of the First Educational Escape Room for Radiography and Radiation Therapy Students
Radiotherapy and Oncology·2025
Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant <scp>GEICAM</scp> Spanish Breast Cancer Group and <scp>TRIO</scp> Translational Research in Oncology Group studies
International Journal of Cancer·2025· 2 citedOpen Access
Supplementary Table S2 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S5 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S9 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S6 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S3 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S3 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S1 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S2 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S6 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S8 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S9 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
page 1 of 4Next →

Frequent Co-authors

John R. Mackey(16), Rodrigo Fresco(12), Cristiano Ferrario(12), Karen A. Gelmon(12), Nathalie LeVasseur(12), Poul H. Sorensen(12), Htoo Zarni Oo(12), Gian Luca Negri(12), Victor Tse(12), Sandra E. Spencer Miko(12), Grace Cheng(12), Gregg B. Morin(12), Sonia V. del Rincón(12), Tiziana Cotechini(12), Christophe Gonçalves(12), Charles C.T. Hindmarch(12), Wilson H. Miller(12), Mehdi Amiri(12), Tayebeh Basiri(12), Victor Villareal-Corpuz(12)